Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givastomig in Advanced or Metastatic Solid Tumors
NCT04900818Phase 1Recruiting
- Sponsor
- I-Mab
- Start
- Jun 2021
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of givastomig in solid tumor, gastric cancer (GC), gastroesophageal junction carcinoma (GEJ) and 3 more, sponsored by I-Mab. Primary endpoints: Dose-limiting toxicities at 28 days, Adverse Events and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
givastomig
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction carcinoma (GEJ)esophageal adenocarcinoma (EAC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04900818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900818.